Company Logo CKD drug development is shifting toward disease-modifying and cardiorenal therapies, creating opportunities in early detection, high-risk screening, combinations and licensing Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of more than 90 companies and over 100 marketed and investigational drugs within the global chronic kidney disease market. The report evaluates therapies by development stage, product type, molecule type, route of administration, clinical status, and therapeutic technology.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.